CONDOLUCI, A., L. T. DI BERGAMO, P. LANGERBEINS, M. A. HOECHSTETTER, C. D. HERLING, L. DE PAOLI, J. DELGADO, K. G. RABE, M. GENTILE, Michael DOUBEK, F. R. MAURO, G. CHIODIN, M. MATTSSON, J. BAHLO, G. CUTRONA, Jana KOTAŠKOVÁ, C. DEAMBROGI, K. E. SMEDBY, V. SPINA, A. BRUSCAGGIN, W. WU, R. MOIA, E. BIANCHI, B. GERBER, E. ZUCCA, S. GILLESSEN, M. GHIELMINI, F. CAVALLI, G. STUSSI, M. A. HESS, T. S. BAUMANN, A. NERI, M. FERRARINI, R. ROSENQUIST, F. FORCONI, R. FOA, Šárka POSPÍŠILOVÁ, F. MORABITO, S. STILGENBAUER, H. DOHNER, S. A. PARIKH, W. G. WIERDA, E. MONTSERRAT, G. GAIDANO, M. HALLEK a D. ROSSI. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. Washington DC, USA: American Society of Hematology, 2020, roč. 135, č. 21, s. 1859-1869. ISSN 0006-4971. Dostupné z: https://dx.doi.org/10.1182/blood.2019003453.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia
Autoři CONDOLUCI, A., L. T. DI BERGAMO, P. LANGERBEINS, M. A. HOECHSTETTER, C. D. HERLING, L. DE PAOLI, J. DELGADO, K. G. RABE, M. GENTILE, Michael DOUBEK (203 Česká republika, domácí), F. R. MAURO, G. CHIODIN, M. MATTSSON, J. BAHLO, G. CUTRONA, Jana KOTAŠKOVÁ (203 Česká republika, domácí), C. DEAMBROGI, K. E. SMEDBY, V. SPINA, A. BRUSCAGGIN, W. WU, R. MOIA, E. BIANCHI, B. GERBER, E. ZUCCA, S. GILLESSEN, M. GHIELMINI, F. CAVALLI, G. STUSSI, M. A. HESS, T. S. BAUMANN, A. NERI, M. FERRARINI, R. ROSENQUIST, F. FORCONI, R. FOA, Šárka POSPÍŠILOVÁ (203 Česká republika, domácí), F. MORABITO, S. STILGENBAUER, H. DOHNER, S. A. PARIKH, W. G. WIERDA, E. MONTSERRAT, G. GAIDANO, M. HALLEK a D. ROSSI (garant).
Vydání Blood, Washington DC, USA, American Society of Hematology, 2020, 0006-4971.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30205 Hematology
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 22.113
Kód RIV RIV/00216224:14110/20:00117894
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1182/blood.2019003453
UT WoS 000535968000010
Klíčová slova anglicky chronic lymphocytic leukemia; prognostic score
Štítky 14110212, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 19. 1. 2021 14:21.
Anotace
Most patients with chronic lymphocytic leukemia (CLL) are diagnosed with early-stage disease and managed with active surveillance. The individual course of patients with early-stage CLL is heterogeneous, and their probability of needing treatment is hardly anticipated at diagnosis. We aimed at developing an international prognostic score to predict time to first treatment (TTFT) in patients with CLL with early, asymptomatic disease (International Prognostic Score for Early-stage CLL [IPS-E]). Individual patient data from 11 international cohorts of patients with early-stage CLL (n = 4933) were analyzed to build and validate the prognostic score. Three covariates were consistently and independently correlated with TTFT: unmutated immunoglobulin heavy variable gene (IGHV), absolute lymphocyte count higher than 15 x 10(9)/L, and presence of palpable lymph nodes. The IPS-E was the sum of the covariates (1 point each), and separated low-risk (score 0), intermediate-risk (score 1), and high-risk (score 2-3) patients showing a distinct TTFT. The score accuracy was validated in 9 cohorts staged by the Binet system and 1 cohort staged by the Rai system. The C-index was 0.74 in the training series and 0.70 in the aggregate of validation series. By meta-analysis of the training and validation cohorts, the 5-year cumulative risk for treatment start was 8.4%, 28.4%, and 61.2% among low-risk, intermediate-risk, and high-risk patients, respectively. The IPS-E is a simple and robust prognostic model that predicts the likelihood of treatment requirement in patients with early-stage CLL. The IPS-E can be useful in clinical management and in the design of early intervention clinical trials.
Návaznosti
LQ1601, projekt VaVNázev: CEITEC 2020 (Akronym: CEITEC2020)
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020
NV19-03-00091, projekt VaVNázev: Komplexní prognostický a prediktivní panel pro pacienty s chronickou lymfocytární leukémií: nástroj sekvenování nové generace vhodný pro klinickou praxi i studium genetického pozadí průběhu choroby
Investor: Ministerstvo zdravotnictví ČR, Comprehensive prognostic and predictive panel for chronic lymphocytic leukemia: a next-generation sequencing tool suitable for clinical practice and study of genetic architecture behind the disease progress
VytisknoutZobrazeno: 30. 8. 2024 09:19